SARDs are a heterogeneous group of disorders characterized by dysregulation of the immune system, that starts to turn against the body’s own tissues. Major SARDs include systemic lupus erythematosus, rheumatoid arthritis, systemic sclerosis and Sjögren’s syndrome. These diseases can affect multiple organs and share common symptoms such as fatigue, fever, joint pain and skin rash. Diagnosis relies on a combination of clinical assessment and specific autoantibody tests. Early diagnosis is crucial to initiate appropriate therapy and slow down disease progression.
The PM/Scl complex is a nucleolar macromolecular complex made up of more than 10 proteins. The two most relevant autoantigenic protein components identified are PM/Scl-75 and PM/Scl-100. Anti-PM/Scl autoantibodies are a subtype of antinucleolar antibodies and are an important diagnostic and prognostic marker for systemic rheumatic diseases, particularly for polymyositis/systemic sclerosis overlap syndrome (PM/SSc). They can also be detected sporadically in other conditions such as inclusion body myositis, Sjögren’s syndrome, systemic lupus erythematosus (SLE) and acquired hemophilia.
Serum, EDTA plasma, heparin plasma, citrate plasma
Immunoblot
Fasting for at least 8-12 hours before sampling
Refer to the Health Service Charter to check storage conditions
+2/+8°C
This test provides the quantitative determination of total tau protein to support the diagnosis of Alzheimer’s disease.
This test provides the quantitative determination of tau protein phosphorylated at threonine 181 (pTau181), to support the diagnosis of Alzheimer’s disease.
Test for the determination of human autoantibodies against NMDAR to support the diagnosis of paraneoplastic neurological syndromes with an intermediate-risk phenotype.
Subscribe to our newsletter to be always updated.